/PRNewswire/ Novo Holdings today announced its financial results for 2023 . Strong Investment Portfolio performance, and growth of the Novo Group companies.
Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk, plans to open an office in India this year to tap innovation and a growing healthcare market, its CEO Kasim Kutay said on Tuesday. The firm, whose assets under management rose to 149 billion euros ($163 billion) at the end of 2023 from 108 billion a year earlier, manages a portfolio of 170 companies across life sciences and capital investments in equities, fixed-income assets, and real estate. It has seen a surge in revenue from Novo Nordisk, the maker of blockbuster obesity drug Wegovy and diabetes treatment Ozempic.
Kasim Kutay, CEO of Novo Holdings, cites Novo Nordisk as the company s figurehead, thanks to robust sales of drugs such as Wegovy and Azempic. These financial results mean that Novo Holdings has a.
By Jacob Gronholt-Pedersen COPENHAGEN (Reuters) - Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk, plans to open an office in India this year to tap innovation and a growing healthcare market, its CEO Kasim Kutay.
Notice for the Annual General Meeting of Novo Nordisk A/S finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.